Skip to end of metadata
Go to start of metadata
You are viewing an old version of this page. View the current version.
Compare with Current
View Page History
« Previous
Version 49
Next »
Project Scope |
This project team will define best practices for ensuring that similar types of adverse events are considered together for purposes of safety analyses. This project will develop efficient standardised processes and analyses that can leverage new technologies. |
Objectives & Deliverables | Timelines |
---|
Complete White Paper final draft | Q2 2023 |
Project Members | Organisation |
---|
Ashik Chowdhury | Cytel |
Barbara Hendrickson | AbbVie |
Brian Panik | MedAssessment |
Charles Beasley | Independent |
Clio Wu | Chinook Therapeutics |
Daniel Wong | Genentech |
Emily Goren | Seagen |
Gayathri Mahadevan | Astrazeneca |
Greg Ball | ASAPprocess |
Jacob Rotmensch | Genentech |
Jonathan Haddad | GSK |
Jyoti Agarwal | Gilead |
Hannah Palac | AbbVie |
Harini Kunduru | Daiichi Sankyo |
Heather Robinson | Bioxcel Therapeutics |
Karen Wade | Rhoworld |
Ketan Durve | Janssen Research & Development |
Kimberly Umans | Biogen |
Mary Nilsson | Eli Lilly |
Mengchun Li | TB Alliance |
Mika Tsujimoto | Eli Lilly |
Nhi Beasley | FDA |
Pranav Soanker | Pfizer |
Radhika M. Rao | AbbVie |
Ramaiah Muvvala | Inductive Quotient |
Rebeka Revis | IQVIA |
Renee Halsing | Genentech |
Scott Proestel | FDA |
Shayami Thanabalasundrum | Exelixis |
Sunil Kumar Shantharaju | Boehringer |
Suwen Li | Roche |
Vaishali Popat | FDA |
Ying (Heather) Hao | Prothena |